Redefining the NAFLD/NASH Referral PathwayA hepatologist's perspective

Dr. Jörn Schattenberg
Professor of Medicine and Director
Metabolic Liver Research Program

University Medical Center Mainz, Germany


With the rising prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), it's important for clinicians to be able to use their resources wisely and have an effective strategy for detecting and managing these patients.

In this video from our expert series on liver disease, watch as Dr. Schattenberg discusses the epidemiology of NAFLD and NASH, the challenges they present in clinical care, and how he sees noninvasive tests like the Enhanced Liver Fibrosis (ELF™) Test being useful in the patient referral pathway.

Dr. Schattenberg

Jörn M. Schattenberg, MD, is a professor of medicine and director of the Metabolic Liver Research Program at the University Medical Center Mainz, Germany. He received his medical degree in 2002 after studying at the University of Mainz (Germany) and Tulane University in New Orleans (U.S.). He completed his postdoctoral training at the Albert-Einstein College of Medicine, New York. He is board-certified in internal medicine, gastroenterology and hepatology, and infectious disease.

Prof. Schattenberg launched the Metabolic Liver Research Program at the University Medical Center in Mainz. His primary research interests focus on translational sciences of liver injury and the development of therapeutic interventions and novel biomarkers in acute and chronic liver disease.

Prof. Schattenberg acts as the lead principal investigator in various phase II and III clinical trials, is a member of the scientific committee of the United European Gastroenterologist (UEG), and a member of the editorial boards of Hepatology and Alimentary Pharmacology & Therapeutics.